Galenic's patented ALGAE-TIDE debuts at 25th World Congress of Dermatology (WCD)

SINGAPORE,July 10,2023 -- French premiumskincare brand Galenic made a stunning debut at the 25th World Congress of Dermatology (WCD) with its two major scientific and technological advances,the patented ALGAE-TIDE and the VC ActiveAnchor™technology. The WCD,commencing this year on July 28,is one of the most important annual events in the world of skincare. The prestigious event brought together renowned dermatology experts from across the globe,and provided the perfect platform for Galenic to showcase their pathbreaking technological achievements.

Galenic was founded in Paris,France,in 1978 by Dr. Pierre Fabre,a renowned pharmacist and botanist. The firm has consistently been at the forefront of the convergence of medical technology and beauty. Their unwavering commitment to developing pharmaceutical-grade skincare products,combined with 45 years of dedicated research in dermatology,has resulted in an impressive collection of 41 product patents. Galenic's cutting-edge transdermal penetration technology,known as ActiveAnchor™,has further propelled their innovative research and positioned them as pioneers in the field.

One of the key highlights at this year's WCD was the long-awaited unveiling of Galenic's patented ALGAE-TIDE,the culmination of over two decades of intensive research. As early as 1997,Dr. Fabre,a specialist in phytomedicine,drew inspiration from a groundbreaking article mentioning the advanced research into new anti-aging pathways in the journal NATURE: "The enhancement of Klotho expression can effectively delay aging". He was also the first to discover that snow algae extract could boost the expression of Klotho genes. Under his leadership,the R&D team at the Galenic Skincare Laboratory collected rare snow algae from the Spitsbergen Mountains in Norway and,after years of experimental research,enhanced the expression of Klotho gene with the snow algae extract by +365%. The anti-aging research on snow algae extract continues to push the boundaries of scientific exploration,demonstrating the brand's strong scientific research capabilities. The findings have been published in the prestigious international medical journal,the Journal of Investigative Dermatology.

Scientific research is an ongoing journey,and Galenic is continuing its endeavor to develop patented ALGAE-TIDE that can not only activate Klotho gene expression by +365%,but also provide triple collagen care,resulting in greater,faster,and more stable collagen production. The innovation combined the snow algae extract with its exclusive Rheolique™ and achives high efficacy by Galenic's 45-year proprietary ActiveAnchor™TECH. Inhibiting inflammation-related ageing and activating cellular autophagy provide a new innovative approach to combat both endogenous and extrinsic aging and achieve a holistic anti-aging effect. Galenic incorporates patented ALGAE-TIDE into its third generation of Couture Secret d'Excellence Active Cream. Through in-vitro research and clinical testing,the patented solution can promote the synthesis of various collagen types,including types I,III,IV,XVII,penetrate deeply into the lower layer of the skin,firm and lift the skin,and effectively resist aging.

In addition,Galenic's proprietary research into what the firm refers to as "Golden-3 Principles of Vitamin C" has captured the attention of dermatology professionals worldwide,while its product Galeniceuticals [N°1] has been recognized and welcomed by its many users. Thanks to Galenic's extensive research on pure form of vitamin C,the firm has successfully overcome the limitations of concentration,activity,and transdermal efficiency,revolutionizing these three aspects. The outcomes achieve by applying the "Golden-3 Principle of Vitamin C" speak for themselves: a formulation of 20% pure form of Vitamin C,laboratory-grade independent light-proof packaging,and the exclusive VC ActiveAnchor™ technology. Galenic's [N°1] increased the transdermal efficiency by 43% over other 20% VC products. In addition,its proprietary VC ActiveAnchor™technology allows the VC ingredient to accurately target the melanocyte areas to efficiently inhibit melanin production and truly achieve rapid whitening with a single dose. The groundbreaking study has also been published in the Journal of Cosmetics,Dermatological Sciences and Applications.

Galenic has earned the respect of top dermatologists worldwide thanks to its scientific accomplishments and efficacy results. Moving forward,Galenic remains fully committed to the research and development of high-end skincare products at the dermatology-grade level. Their unwavering dedication to creating scientifically advanced and sustainable skincare solutions for discerning consumers worldwide solidifies their position as leaders in the industry.